Press Releases

Press Releases

  • August 15, 2022
    Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
  • August 1, 2022
    Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
  • July 8, 2022
    Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
  • June 29, 2022
    Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
  • May 19, 2022
    Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
  • May 17, 2022
    Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
  • May 13, 2022
    Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
  • May 10, 2022
    Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting
  • May 5, 2022
    Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
  • April 21, 2022
    Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations